They found that SGLT2 inhibitors may reduce the risk of asthma, pneumonia, exacerbations in patients with chronic obstructive pulmonary disease, improve pulmonary arterial hypertension in patients with interstitial lung disease, and serve as a therapeutic target for early-stage lung adenocarcinoma (Scafoglio et al., 2018; Qiu et al., 2021; Pradhan et al., 2022; Wu et al., 2022). This evidence concerns the gene SLC5A2 and asthma.